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· RESULTS:Aftersix-monthmedicalintervention,the meandiurnalIOPofFCswaslowerthanPGAs(MD-1.14, 95%CI-1.82to-0.46, =0.001);thepercentageoftarget IOPachievingbetweenFCsandPGAsshowedno significantdifference(RR1. 18, 95%CI0.97to1.43, =0.10 [1] .In CollaborativeInitialGlaucomaTreatmentStudy,almost three-fourthsofthepatientsrandomizedtothemedication armrequiredtwoormoreagentstoachievealowertarget IOP [2] .Benzalkoniumchloride(BAK)isacommonlyused preservativeineyedrops,whichhasbeenprovedtocause dose-dependenttoxiceffectstotheocularsurface,evento thecornealendotheliaandtrabecularmeshworkcells [3] [4] [5] . Moreapplicationofeyedropsmeansmoreexposuresto BAK,whichmightincreasetheincidenceofothereye disorders.Thefixedcombinationmightbeabletosolvethe formerproblem.Themainfixedcombinationsutilized currentlyarethefixedcombinationof0.005%latanoprost and0.5%timolol (FCLT),0.04%bimatoprostand0.5% timolol(FCMT),0.004%travoprostand0.5%timolol, 0.0015%tafluprostand0.5%timolol (FCTT).Latanoprost,
www.ijo.cn 栽藻造押8629原愿圆圆源缘员苑圆 8629-82210956 耘皂葬蚤造押ijopress岳员远猿援糟燥皂 travoprost,tafluprostbelongto prostaglandinanalogs (PGAs).Theclassificationof bimatoprost hasbeen controversialassomescholarsclassifieditasprostaglandin analogs,whilesomeotherssorteditasprostamideforits chemicalstructure [6] .Latanoprost,travoprostandtafluprost lowertheIOPmainlybyincreasinguveoscleraloutflow [7] [8] , whilethephysiologicalmechanismsofbimatoproststill remaintobeclarified,butreportsshowedthatincreasing uveoscleraloutflowmightbeoneofitssignificantmethods inloweringIOP [6, 9] .Nevertheless,thesefouragentsshowed similarefficacyinreducingIOP [10] .Inthisanalysis, bimatoprostisclassifiedasPGAs.Timolol,belongingto beta-blockers,reducesIOPthroughmanycomplicated mechanisms,butithasbeenprovedthatitmainlyfunctions bydecreasingtheproductionofaqueoushumor [11] The recommendeddoseoftimololvariesfromoncetotwice daily.Thefixedcombinationsarerecommendedtouseonce daily. TworecentMeta-analysesdemonstratedthatthefixed combinationsoftimololandPGAs (FCs)weremore efficaciousthantheindividualcomponentsmonotherapy, andbroughtalowerriskofconjunctivalhyperemia [12] [13] . However,thetreatmentdurationofmoststudiesincludedin thesetwoanalyseswasrelativelynotlongenough,which wasinconsistentwiththefactthatasachroniccondition, glaucomarequireslong-termintervention.Toevaluatethe long-termsafetyandefficacyofthefixedcombinations comparedwithPGAs,thisMeta-analysiswasconducted. Search termsusedinourstudyincluded "glaucoma","ocularhypertension","timolol","prostaglandin analog","latanoprost", "travoprost","bimatoprost"and "tafluprost".ThelastsearchwasconductedinMarch,2015. Referencesofeligiblearticlesandreviewarticleswerealso handsearchedforrelevantcitations. Study Selection and Data Extraction Twoauthors independentlyscreenedthetitlesandabstractsofreportsand excludedobviouslyirrelevantreports.Thefulltextsof potentiallyeligibletrialswereobtainedandassessedin detail. Thestudydesign, patientcharacteristics, interventions,andoutcomeswererecordedbytworeviewers independently,andwerecross-checkedforaccuracy.Any disagreementswereresolvedbyconsensus. RiskofBiasAssessment Eligiblestudieswereassessedfor riskofbiasaccordingtotheCochraneHandbookfor SystematicReviewsofInterventionsv5.1.0.Thecomponents assessedwere"randomsequencegeneration","allocation concealment","blindingofparticipantsandpersonnel", "blindingofoutcomeassessment","incompleteoutcome data", "selectivereporting", and"otherbiases".Each componentwasjudgedas"lowrisk","unclearrisk",or"high riskofbias"asoutlinedintheCochraneHandbook. [15] ;8werelessthan6mo;theremaining5 articles [16] [17] [18] [19] [20] mettheinclusioncriteriaforthisreview.The relevantarticleselectionprocessisdemonstratedinFigure1. StudyCharacteristics Table1showsthecharacteristicsof theincluded5studies.Allofthestudieswererandomized controlleddouble-maskedmulticenterclinicaltrialswitha washoutorrun-inperiod.Fourtrialsrecruitedpatientswith OHTorOAG;onetrialenrolledpatientswithOAG,OHT, orCACG.TheinterventionoftreatmentgroupswasFCs (threelatanoprost,onebimatoprostandonetafluprost), whichwasusedoncedailyinthemorning.Theintervention ofcontrolgroupincludedinthisreviewwasthesamePGAs monotherapyoncedailyinthemorningorevening.Allthe trialsmeasuredtheIOPusing Goldmannapplanation tonometer.TwostudiesreportedmeandiurnalIOPmeasured at8:00,10:00,and16:00 [17] [18] .Threetrialdidnotreport extractabledataofmeanIOP.Asforthesafetyoutcomes, onlyonestudymeasuredthechangeofcornealendothelial celldensityandcornealthickness [19] ,fourtrialsreportedthe incidenceofconjunctivalhyperemiaandeyeirritation [16] [17] [18] 20] . RiskofBias Themethodologicalqualityofthestudieswas generallygood(Figure2).Threestudiesdescribedthe methodsofsequencegeneration,twotrialonlymentioned "randomlyassigned"withoutsufficientinformationfor judgment [17, 20] .Twostudiesdescribedthemethodsof allocationconcealment,sowerejudgedas"lowriskofbias" [18] [19] . Allfivetrialsweredouble-maskedoftheparticipantsand studypersonnel.Onlytwostudiesdescribedapartof methodsofblindingoutcomeassessment [18] [19] ,theremaining threedidnotreportmaskindetails.Butoutcome measurementisnotlikelytobeinfluencedbylackingof blinding,sowestilljudgedthemas"lowriskofdetection bias".Withdrawalwerenotevenlydistributedbetween groupsinthreestudies [16, [18] [19] ,moreadverseeventor uncontrollediIOPwerefoundinPGAsmonotherapygroup. Onestudy [20] didnotreporttheoutcomeofcornealthickness intheresult,whichwasmeasuredduringthefollow-up,so wejudgeditas"highriskofreportingbias".Theprotocols ofotherfourtrialswerenotavailable,sowehadinsufficient informationforjudgment.Onlyintwotrialsthepatients underwentawashoutofocularhypertensivemedication [16, 20] , otherstudiesallusedtimololduringthe2-4wkrun-inperiod, sincethisreviewwasattempttoassessthelong-termeffect offixedcombinationofPGAsandtimolol,lackingwashout wasnotlikelytoinfluencetheoutcomeofinterestatleast 6molater.Onestudywasjudgedas"highriskofbias" becauseofbaselineimbalance [18] .Sinceonlyfivetrialswere includedinthisreview,funnelplotwasnotperformedto assesspublicationbias. MeanDiurnalIntraocularPressure Twotrials [17] [18] 
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PercentageofParticipantsWhoAchievedtheTarget
IntraocularPressure Threetrials [16] [17] [18] reporteddataon percentageofparticipantswhoseIOP<18mmHgattheend ofthetrials.Two [17] [18] ofthesetrialsassessedlatanoprostand theotherone [16] usedbimatoprost.Accordingtotheresult,the percentageofachieving18mmHgbetweenFCsandPGAs showednosignificantdifference(RR1.18,95%CI0.97to 1.43, =0.10) (Figure4) IncidenceofEyeIrritation Fourtrials [16] [17] [18] 20] reporteddata oneyeirritation.Twotrials [17] [18] providedtheincidenceofeye irritationasawholesymptom,whiletheothertwo [16, 20] [21] . Accordingtotheresultofthepresentanalysis,theIOPin participantsfromFCsgroupwaslower( =0.001)thanthe PGAsgroup.Thisresultisconsistentwiththefindingsof otherinvestigators [12] [13] 22] ,althoughoneofthemshowedthat therewereslightdifferentiationsbetweentheefficacyof threePGAs/timololFCs [13] .Asthetimesofpeakeffectof timololandPGAsaredifferent(timololis2hafterdosing, PGAsis12h),theloweredIOPobservedduringtheday-time mightbemainlyaffectedbytimolol.Thus,therealefficacies ofFCsadministeredinthemorningmightbeunderestimated [23] . Aposthocanalysis [15] alsoreportedthefluctuationofIOPin FCsgroupwaslowercomparedtolatanoprostmonotherapy ( =0.010).Arecentanimalstudy [24] hadfoundthat fluctuationsinIOPincreasedthetrabecularmeshwork extracellularmatrix,whichisprobablyariskfactorfor glaucomatousprogression.TheeffectofFCsonboth loweringandstabilizingtheIOPmaymakeitamore reasonablechoiceforintervention. The18mmHgwasrecognizedasarelativelysafe quantitativevaluewhichwassetbytheinvestigatorsfrom theseRCTsasauniversallyundifferentiatedtargetIOPfor thoseparticipantsanditisalsorecommendedasinitial superiorlimitIOPforallglaucomapatientsinclinical practice [25] .However,attheendofthe6mo,thedifferenceof proportionsofwhoattainedtheIOPwithin18mmHgfrom twogroupswasnotdetected.AsthesafeIOP,ortargetIOP, variesindifferentpatientsaccordingtodifferentconditions, itseemedthatthesignificanceofthisdatummightnotbeso crucialforthereasonandarecentreportsuggestedthat failuretousetargetIOPdoesnotleadtobadoutcomes [26] .
Meta-analysisofocularhypotensivedrugs
Glaucomaisnowrecognizedasachronicandprogressive neurodegenerativediseasewhichisaleadingcauseof blindnessworldwidely [27] .Thepatientssufferingfrom glaucomaneedlongtermcares.Ithasbeenreportedthatthe effectofloweringIOPonretinalganglioncells(RGCs) apoptosisrequiresalongerfollow-up( fiveyearspost intervention)tobedetected [28] .Thus,treatmentdurationof 6moto1yisfarfromadequatetodrawaconclusionover visualfieldchange.Asaresult,wedidnotperformany Meta-analysistoevaluatetheincidenceofvisualfield change. Inaspectofsafety,itwasdeemedfromthisMeta-analysis thattheFCsgroupsdidnotperformbetterthanPGAs monotherapy.InthisMeta-analysis,boththeincidenceof hyperemia( =0.06)andeyeirritationsyndromes( =0.12) showednostatisticallysignificantdifferences.Therational explanationsmightbethevariedconcentrationsof preservativesandPGAsinthosemedicationsmighthave differentiatedsideeffects.An experimentshowed differentproportionsofcell survivalindifferent common-usedanti-glaucomaeyedrops [3] .Hypotheticallyand theoreticallyspeaking,itwasthoughtthatthelessexposure toBAKmightleadtoalowerincidenceofhyperemiaand eyeirritationsyndromesasthetoxicityofBAKis dose-dependent [3] [4] [5] .AlthoughtheFCTTwaspreservative free,itseemedthatthesideeffectswereincreasedwiththe combinationoftimolol [20] .OurMeta-analysisreacheda differentoutcomewithtworecentMeta-analyses [12] [13] .The detailedmechanismsarestillwaitingtobefurtherexplored. Regarding thecornealadverseeffects,althoughno Meta-analysiswascarriedout,theonlydatumshowedno differencesbetweentwointerventiongroupsincentral endothelialcelldensity(=0.45)andcentralcorneal thickness ( =0.23).Thepossiblecomprehensionforthis mightbeforthereasonthatthesideeffectsofBAKto cornealendotheliaisfeeble ,althoughthe experimentshowedBAKiseasilytocauseculturedcorneal andconjunctivalepithelia'sdeath [3] . SomelimitationsofthisMeta-analysisshouldbedetailedly discussed.Firstly,themajorityofthesubjectsinthisanalysis fromthethreearticleswhichgavethedataoftheraceratios werewhite(72.2%).Itwasreportedthat,comparedwith latanoprost,travoprostwasmoreeffectiveinloweringIOPin blackthannonblackstatistically [29] ,althoughtravoprostwas notdiscussedinthisanalysis.Thus,theresultsmightnotbe comprehensivelyapplicabletoall theethnicgroups. Secondly,theefficacyoftimololinanoticeableproportion whohasappliedtimololforalongtermwoulddecrease [30] , whichwascalled"longtermdrift".Thephenomenonwas notmentionedinthesefourarticles,whichremainedtobe furtherstudied.Thirdly,thecriterionoftargetIOP(18mmHg) intheseresearcheswasnotobjectiveenough.Infact,the definitionoftargetIOPhasbeencontroversialeversince:the AmericanAcademyofOphthalmologydefineditas"arange ofIOPadequatetostopprogressivepressureinducedinjury" [31] ; theEuropeanGlaucomaSocietyguidelinesgaveadefinition as"anestimateofthemeanIOPobtainedwithtreatmentthat isexpectedtopreventfurtherglaucomatousdamage" [32] ;the definitionfromWorldGlaucomaAssociationis"anestimate ofthemeanIOPatwhichtheriskofdecreasedvision-related qualityoflifeduetoglaucomaexceedstheriskofthe treatment" [33] ;whiletheNationalCollaboratingCentrefor AcuteCareofUKgavethedefinitioninfra:"adynamic, clinicaljudgementaboutwhatlevelofintraocularpressureis consideredbythehealthcareprofessionaltreatingthepatient tobe sufficientlylowto minimizeorarrestdisease progressionoronsetandavoiddisabilityfromvisionloss withinaperson'sexpectedlifetime" [34] .Thesevaried definitionsalsodescribedafactthattherewasnogenerally acknowledgedconsensusindefiningtargetIOP.Besides,the targetIOPshouldbeindividualizedindifferentsituations [26] . 
